KYTX 8-K: SEC filing

Kyverna Therapeutics

Filed with the SEC on Nov 12, 2026 · accession 0001193125-26-457040

KYTX filed a 8-K (current report) with the SEC on Nov 12, 2026. A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Summary of the filing

Kyverna Therapeutics issued a press release providing a business update and reporting financial results for the quarter ended September 30, 2026.

For details, click here →How to read a 8-K →

Key details

RegistrantKyverna Therapeutics, Inc.

Chief financial officerGregory Martini

✦ Ask GOAX AI about this filing — what it means for KYTX, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for KYTX?

Click here

Frequently asked questions

What did KYTX file with the SEC on Nov 12, 2026?

KYTX filed a 8-K (SEC filing). Kyverna Therapeutics issued a press release providing a business update and reporting financial results for the quarter ended September 30, 2026.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other KYTX SEC filings

Get alerts when KYTX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

KYTX overview KYTX analysis KYTX news Latest SEC filings